2022-09-01 2023-08-31 false Capium Accounts Production 1.1 09743098 bus:AbridgedAccounts 2022-09-01 2023-08-31 09743098 bus:FRS102 2022-09-01 2023-08-31 09743098 bus:AuditExemptWithAccountantsReport 2022-09-01 2023-08-31 09743098 bus:SmallCompaniesRegimeForAccounts 2022-09-01 2023-08-31 09743098 bus:PrivateLimitedCompanyLtd 2022-09-01 2023-08-31 09743098 2022-09-01 2023-08-31 09743098 2023-08-31 09743098 bus:RegisteredOffice 2022-09-01 2023-08-31 09743098 core:WithinOneYear 2023-08-31 09743098 core:AfterOneYear 2023-08-31 09743098 bus:Director1 2022-09-01 2023-08-31 09743098 bus:Director1 2023-08-31 09743098 bus:Director1 2021-09-01 2022-08-31 09743098 2021-09-01 09743098 bus:LeadAgentIfApplicable 2022-09-01 2023-08-31 09743098 2021-09-01 2022-08-31 09743098 2022-08-31 09743098 core:WithinOneYear 2022-08-31 09743098 core:AfterOneYear 2022-08-31 09743098 bus:EntityAccountantsOrAuditors 2021-09-01 2022-08-31 09743098 bus:OrdinaryShareClass1 2022-09-01 2023-08-31 09743098 bus:OrdinaryShareClass1 2023-08-31 09743098 bus:OrdinaryShareClass1 2021-09-01 2022-08-31 09743098 bus:OrdinaryShareClass1 2022-08-31 09743098 core:PlantMachinery 2022-09-01 2023-08-31 09743098 core:PlantMachinery 2023-08-31 09743098 core:PlantMachinery 2022-08-31 09743098 core:ComputerEquipment 2022-09-01 2023-08-31 09743098 core:ComputerEquipment 2023-08-31 09743098 core:ComputerEquipment 2022-08-31 09743098 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-08-31 09743098 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2022-08-31 09743098 core:CostValuation core:Non-currentFinancialInstruments 2023-08-31 09743098 core:CostValuation core:Non-currentFinancialInstruments 2022-08-31 09743098 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2023-08-31 09743098 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2023-08-31 09743098 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2023-08-31 09743098 core:Non-currentFinancialInstruments 2023-08-31 09743098 core:Non-currentFinancialInstruments 2022-08-31 09743098 core:ShareCapital 2023-08-31 09743098 core:ShareCapital 2022-08-31 09743098 core:RetainedEarningsAccumulatedLosses 2023-08-31 09743098 core:RetainedEarningsAccumulatedLosses 2022-08-31 09743098 dpl:Item1 2022-09-01 09743098 dpl:Item1 2023-08-31 09743098 dpl:Item1 2021-09-01 09743098 dpl:Item1 2022-08-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 09743098
England and Wales

 

 

 

A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD


Abridged Accounts
 


Period of accounts

Start date: 01 September 2022

End date: 31 August 2023
Chartered Accountants' report to the board of directors on the preparation of the unaudited statutory accounts of A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD for the year ended 31 August 2023
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD for the year ended 31 August 2023 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the companys accounting records and from information and explanations you have given us.
As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/en/members/regulations-standards-and-guidance
This report is made solely to the Board of Directors of A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD , as a body, in accordance with the terms of our engagement letter dated 01 September 2022. Our work has been undertaken solely to prepare for your approval the accounts of A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD and state those matters that we have agreed to state to the Board of Directors of A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD , as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD . You consider that A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD . For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts
31 August 2023



....................................................
PHS Associates Acc Co
223 St Albans Road
Watford
WD24 5BH
31 May 2024
1
 
 
Notes
 
2023
£
  2022
£
Fixed assets      
Tangible fixed assets 3 38,471    551 
38,471    551 
Current assets      
Debtors: amounts falling due within one year 1,864    3,842 
Cash at bank and in hand 105,733    123,110 
107,597    126,952 
Creditors: amount falling due within one year (16,622)   (55,586)
Net current assets 90,975    71,366 
 
Total assets less current liabilities 129,446    71,917 
Net assets 129,446    71,917 
 

Capital and reserves
     
Called up share capital 4 100    100 
Profit and loss account 129,346    71,817 
Shareholders' funds 129,446    71,917 
 


For the year ended 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 31 May 2024 and were signed by:


-------------------------------
Amiee Anjali VYAS
Director
2
General Information
A VYAS MEDICAL T/A DOCTOR AMIEE FACIAL AESTHETICS & SKIN LTD is a private company, limited by shares, registered in England and Wales, registration number 09743098, registration address 223 St. Albans Road, Watford, WD24 5BH.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Going concern basis
The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Taxation
Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.
The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Current and deferred tax assets and liabilities are not discounted
Dividends
Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Plant and Machinery 20% Straight Line
Computer Equipment 20% Straight Line
2.

Average number of employees

Average number of employees during the year was 1 (2022 : 1).
3.

Tangible fixed assets

Cost or valuation Plant and Machinery   Computer Equipment   Total
  £   £   £
At 01 September 2022   2,067    2,067 
Additions 45,000    2,630    47,630 
Disposals    
At 31 August 2023 45,000    4,697    49,697 
Depreciation
At 01 September 2022   1,516    1,516 
Charge for year 9,000    710    9,710 
On disposals    
At 31 August 2023 9,000    2,226    11,226 
Net book values
Closing balance as at 31 August 2023 36,000    2,471    38,471 
Opening balance as at 01 September 2022   551    551 


4.

Share Capital

Allotted, called up and fully paid
2023
£
  2022
£
100 Class A shares of £1.00 each 100    100 
100    100 

3